Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

INTRODUCTION: The PIONEER trial programme showed that, after 52 weeks, the novel oral glucagon-like peptide-1 (GLP-1) analogue semaglutide 14 mg was associated with significantly greater reductions in glycated haemoglobin (HbA1c) versus a sodium-glucose cotransporter-2 inhibitor (empagliflozin 25 mg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Ther
Main Authors: Bain, Stephen C., Hansen, Brian B., Malkin, Samuel J. P., Nuhoho, Solomon, Valentine, William J., Chubb, Barrie, Hunt, Barnaby, Capehorn, Matthew
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6965564/
https://ncbi.nlm.nih.gov/pubmed/31833042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00736-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados